Literature DB >> 11971900

Nuclear import strategies of high risk HPV16 L1 major capsid protein.

Lisa M Nelson1, Robert C Rose, Junona Moroianu.   

Abstract

During the late phase of human papillomavirus (HPV) infection, the L1 major capsid proteins enter the nuclei of host epithelial cells and, together with the L2 minor capsid proteins, assemble the replicated viral DNA into virions. We investigated the nuclear import of the L1 major capsid protein of high risk HPV16. When digitonin-permeabilized HeLa cells were incubated with HPV16 L1 capsomeres, the L1 protein was imported into the nucleus in a receptor-mediated manner. HPV16 L1 capsomeres formed complexes with Kap alpha2beta1 heterodimers via interaction with Kap alpha2. Accordingly, nuclear import of HPV16 L1 capsomeres was mediated by Kap alpha2beta1 heterodimers, required RanGDP and free GTP, and was independent of GTP hydrolysis. Remarkably, HPV16 L1 capsomeres also interacted with Kap beta2 and binding of RanGTP to Kap beta2 did not dissociate the HPV16 L1.Kap beta2 complex. Significantly, HPV16 L1 capsomeres inhibited the nuclear import of Kap beta2 and of a Kap beta2-specific M9-containing cargo. These data suggest that, during the productive stage of infection, while the HPV16 L1 major capsid protein enters the nucleus via the Kap alpha2beta1-mediated pathway to assemble the virions, it also inhibits the Kap beta2-mediated nuclear import of host hnRNP A1 protein and, in this way, favors virion formation.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11971900     DOI: 10.1074/jbc.M200724200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  22 in total

1.  The l2 minor capsid protein of low-risk human papillomavirus type 11 interacts with host nuclear import receptors and viral DNA.

Authors:  J Bordeaux; S Forte; E Harding; M S Darshan; K Klucevsek; J Moroianu
Journal:  J Virol       Date:  2006-08       Impact factor: 5.103

Review 2.  The papillomavirus major capsid protein L1.

Authors:  Christopher B Buck; Patricia M Day; Benes L Trus
Journal:  Virology       Date:  2013-06-22       Impact factor: 3.616

3.  Dissection of a novel nuclear localization signal in open reading frame 29 of varicella-zoster virus.

Authors:  Christina L Stallings; Saul Silverstein
Journal:  J Virol       Date:  2005-10       Impact factor: 5.103

4.  Nuclear import of cutaneous beta genus HPV8 E7 oncoprotein is mediated by hydrophobic interactions between its zinc-binding domain and FG nucleoporins.

Authors:  Zeynep Onder; Junona Moroianu
Journal:  Virology       Date:  2013-12-05       Impact factor: 3.616

Review 5.  DNA damage response is hijacked by human papillomaviruses to complete their life cycle.

Authors:  Shi-Yuan Hong
Journal:  J Zhejiang Univ Sci B       Date:  2017 Mar.       Impact factor: 3.066

6.  Nuclear import of bovine papillomavirus type 1 E1 protein is mediated by multiple alpha importins and is negatively regulated by phosphorylation near a nuclear localization signal.

Authors:  Xue-Lin Bian; Germán Rosas-Acosta; Yu-Chieh Wu; Van G Wilson
Journal:  J Virol       Date:  2006-12-27       Impact factor: 5.103

Review 7.  Papillomavirus assembly: An overview and perspectives.

Authors:  Carla Cerqueira; John T Schiller
Journal:  Virus Res       Date:  2016-11-10       Impact factor: 3.303

8.  Identification of the nuclear localization and export signals of high risk HPV16 E7 oncoprotein.

Authors:  Alixandra A Knapp; Patrick M McManus; Katy Bockstall; Junona Moroianu
Journal:  Virology       Date:  2008-11-08       Impact factor: 3.616

9.  Possible role for cellular karyopherins in regulating polyomavirus and papillomavirus capsid assembly.

Authors:  Gregory Bird; Malinda O'Donnell; Junona Moroianu; Robert L Garcea
Journal:  J Virol       Date:  2008-08-13       Impact factor: 5.103

10.  Nuclear entry of high-risk human papillomavirus type 16 E6 oncoprotein occurs via several pathways.

Authors:  Lucia G Le Roux; Junona Moroianu
Journal:  J Virol       Date:  2003-02       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.